Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011:2011:739751.
doi: 10.1155/2011/739751. Epub 2010 Nov 24.

Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction

Marianne K Kringen  1 , Kari Bente Foss Haug, Runa M Grimholt, Camilla Stormo, Sigrid Narum, Mimi S Opdal, Jan Toralf Fosen, Armin P Piehler, Per W Johansen, Ingebjørg Seljeflot, Jens Petter Berg, Odd Brørs
Affiliations

Genetic variation of VKORC1 and CYP4F2 genes related to warfarin maintenance dose in patients with myocardial infarction

Marianne K Kringen et al. J Biomed Biotechnol. 2011.

Abstract

The aim of this study was to investigate whether the VKORC1*3 (rs7294/9041 G > A), VKORC1*4 (rs17708472/6009 C > T), and CYP4F2 (rs2108622/1347 C > T) polymorphisms were associated with elevated warfarin maintenance dose requirements in patients with myocardial infarction (n = 105) from the Warfarin Aspirin Reinfarction Study (WARIS-II). We found significant associations between elevated warfarin dose requirements and VKORC1*3 and VKORC1*4 polymorphisms (P = .001 and P = .004, resp.), whereas CYP4F2 (1347 C > T) showed a weak association on higher warfarin dose requirements (P = .09). However, analysing these variant alleles in a regression analysis together with our previously reported data on VKORC1*2, CYP2C9*2 and CYP2C9*3 polymorphisms, gave no significant associations for neither VKORC1*3, VKORC1*4 nor CYP4F2 (1347 C > T). In conclusion, in patients with myocardial infarction, the individual contribution to warfarin dose requirements from VKORC1*3, VKORC1*4, and CYP4F2 (1347 C > T) polymorphisms was negligible. Our results indicate that pharmacogenetic testing for VKORC1*2, CYP2C9*2 and CYP2C9*3 is more informative regarding warfarin dose requirements than testing for VKORC1*3, VKORC1*4, and CYP4F2 (1347 C > T) polymorphisms.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Box plot of mean weekly warfarin maintenance dose for combinations of different VKORC1 haplotypes. The boxes represent the values from the 25th to 75th percentile. The middle lines represent the median. The vertical lines extend from the minimum values to the maximam values, excluding outliers and extreme values marked with open circles and asterisk, respectively. The P-value indicates the statistical significance of the difference in mean weekly warfarin dose between patients with or without the VKORC1*2 haplotype (Mann-Whitney test).
Figure 2
Figure 2
Box plot of mean weekly warfarin maintenance dose for combinations of different CYP4F2 genotypes. The boxes represent the values from the 25th to 75th percentile. The middle lines represent the median. The vertical lines extend from the minimum values to the maximum values.
See this image and copyright information in PMC

References

    1. Drapkin A, Merskey C. Anticoagulant therapy after acute myocardial infarction. Relation of therapeutic benefit to patient’s age, sex, and severity of infarction. Journal of the American Medical Association. 1972;222(5):541–548. - PubMed
    1. Aithal GP, Day CP, Kesteven PJL, Daly AK. Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications. The Lancet. 1999;353(9154):717–719. - PubMed
    1. Caldwell MD, Awad T, Johnson JA, et al. CYK4F-2 genetic variant alters required warfarin dose. Blood. 2008;111(8):4106–4112. - PMC - PubMed
    1. D’Andrea G, D’Ambrosio RL, Di Perna P, et al. A polymorphism in the VKORC1 gene is associated with an interindividual variability in the dose-anticoagulant effect of warfarin. Blood. 2005;105(2):645–649. - PubMed
    1. Rieder MJ, Reiner AP, Gage BF, et al. Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. The New England Journal of Medicine. 2005;352(22):2285–2293. - PubMed

Publication types

MeSH terms